ClinicalTrials.Veeva

Menu

Protocol to Assess the Severity of Acute Kidney Injury (AKI)

George Washington University (GW) logo

George Washington University (GW)

Status

Completed

Conditions

Acute Kidney Failure

Treatments

Drug: Furosemide

Study type

Interventional

Funder types

Other

Identifiers

NCT00673244
IRB# 010835

Details and patient eligibility

About

The principal objective is to safely determine if we can identify the severity of Acute Kidney Injury (AKI) early in the course of the disease. Once enrolled, we will draw blood and urine for relevant biomarkers. Our goal is to validate if any of these biomarkers can predict the course of AKI (recovery v. RRT v. death)

Full description

AKI is a very common disease in the intensive care unit. However, despite advances in supportive care, patients with AKI carry a high mortality rate (50% to 70%). The established AKI affects nearly 5 percent of hospitalized persons and as many as 15 percent of critically ill patients. Currently, there are no FDA approved therapeutic agents for the treatment of AKI.

Retrospective studies suggest that the early initiation of renal replacement therapy (RRT) improves outcome. Many clinicians tend to take a "wait and see" approach because they do not want to dialyze a patient who is destined to recover renal function without the need for RRT. Therefore, it is vitally important to know early in the course which patients with AKI are likely to progress to RRT.

Enrollment

77 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 18 years and older
  • Increase in serum creatinine of 0.3 mg/dl within 48 hours or an increase of greater or equal to 150 to 200% from baseline or sustained oliguria(mean urine output of <0.5 cc/kg/hr for 6 hours within 48 hours)
  • Written informed consent
  • Patients who already have a indwelling bladder catheter

Exclusion criteria

  • Voluntary refusal or missing written consent of the patient or the designated legal representative

  • Patients with advanced Chronic Kidney Disease - as defined by a baseline GFR of < 30 ml/min as calculated by the MDRD equation

  • Patients with renal transplantation

  • Pregnancy

  • Patients with an allergy or sensitivity to loop diuretics

  • Patients with a clinical syndrome consistent with pre-renal AKI

    • Defined by fractional excretion of Na of < 1% AND no evidence of the urinary casts, or
    • Patients that are under-resuscitated as deemed by treating clinical team or
    • Patients who are actively bleeding
  • Patients with a clinical syndrome of post-renal AKI

    • Any radiological study that shows hydro-ureter, or
    • Clinical scenario wherein the obstruction is considered a likely possibility of the cause of AKI

Trial design

Primary purpose

Prevention

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

77 participants in 1 patient group

1
Experimental group
Treatment:
Drug: Furosemide

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems